Arcutis Biotherapeutics
(NASDAQ) ARQT
Arcutis Biotherapeutics Financials at a Glance
Market Cap
$3.04B
Revenue (TTM)
$376.07M
Net Income (TTM)
$16.14M
EPS (TTM)
$-0.14
P/E Ratio
-175.34
Dividend
$0.00
Beta (Volatility)
1.21 (Average)
Dividend
$0.00
Beta (Volatility)
1.21 (Average)
Price
$24.53
Volume
1,158,642.423
Open
$24.76
Price
$24.53
Volume
1,158,642.423
Open
$24.76
Previous Close
$24.53
Daily Range
$24.23 - $24.80
52-Week Range
$12.42 - $31.77
Dividend
$0.00
Beta (Volatility)
1.21 (Average)
Price
$24.53
Volume
1,158,642.423
Open
$24.76
Previous Close
$24.53
Daily Range
$24.23 - $24.80
52-Week Range
$12.42 - $31.77
ARQT News
ARQT: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Arcutis Biotherapeutics
Industry
Biotechnology
Sector
Health CareEmployees
354
CEO
Todd Franklin Watanabe
Website
www.arcutis.comHeadquarters
Westlake Village, CA 91361, US
ARQT Financials
Key Financial Metrics (TTM)
Gross Margin
90%
Operating Margin
-3%
Net Income Margin
-4%
Return on Equity
-9%
Return on Capital
-4%
Return on Assets
-4%
Earnings Yield
-0.57%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$3.04B
Shares Outstanding
124.03M
Volume
1.16M
Short Interest
0.00%
Avg. Volume
1.31M
Financials (TTM)
Gross Profit
$339.38M
Operating Income
$12.23M
EBITDA
$2.48M
Operating Cash Flow
$5.63M
Capital Expenditure
$686.00K
Free Cash Flow
$6.31M
Cash & ST Invst.
$220.98M
Total Debt
$6.27M
Arcutis Biotherapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$129.50M
+81.5%
Gross Profit
$117.81M
+82.8%
Gross Margin
90.97%
N/A
Market Cap
$3.04B
N/A
Market Cap/Employee
$8.90M
N/A
Employees
342
N/A
Net Income
$17.39M
+261.2%
EBITDA
$22.13M
+596.6%
Quarterly Fundamentals
Net Cash
$214.72M
+82.9%
Accounts Receivable
$146.23M
+100.1%
Inventory
$22.63M
+55.8%
Long Term Debt
$5.27M
-95.2%
Short Term Debt
$1.00M
+22.0%
Return on Assets
-3.73%
N/A
Return on Invested Capital
-4.03%
N/A
Free Cash Flow
$26.18M
+555.5%
Operating Cash Flow
$26.18M
+3600.7%